Abstract
Background
Invasive breast carcinomas are composed of invasive and noninvasive components in varying proportions and sometimes the two components show different histopathological responses to chemotherapy, however there has been no study as yet comparing the pathological response to chemotherapy of invasive and noninvasive components.
Patients and Methods
A consecutive series of 100 women neoadjuvant chemotherapy with doxorubicin and docetaxel every three weeks before surgery. After the chemotherapy, surgically resected specimens were studied histologically according to the criteria of the Japanese Breast Cancer Society.
Results
Five cases (5/100; 5%) were determined to show Grade 3 pathological response, and 28 cases (28/100; 28%) showed Grade 2 response. There were 6 Grade 3 (6/96; 6%) and 18 Grade 2 (18/96; 19%) invasive component cases. There were 7 Grade 3 (7/82; 9%) and 18 Grade 2 (18/82; 22%) cases showing pathological response in the noninvasive component. With regard to pathological response, there was a strong correlation between the invasive and noninvasive components (p < 0.001). There was also a correlation in pathological response between the invasive component and axillary lymph nodes in individual cases (p = 0.02). There was no correlation between the response of the noninvasive component and axillary lymph nodes. By multivariate analysis, the overall primary tumor response was reflected by the histological response of the invasive component in the primary breast carcinoma.
Conclusion
We suggest that the pathological response of the invasive component of breast carcinoma should be evaluated, which might provide more accurate information for prognosis and treatment decisions.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Abbreviations
- ER:
-
Estrogen receptor
- PR:
-
Progesterone receptor
- CR:
-
Complete response
- PR:
-
Partial response
- NC:
-
Stable disease
- PD:
-
Progressive disease
References
Hortobagyi GN: Multidisciplinary management of advanced primary and metastatic breast cancer.Cancer 74: 416–423, 1994.
Hortobagyi GN: Recent progress in the clinical development of docetaxel (taxotere).Semin Oncol 26: 32–36, 1999.
Honkoop AH, van Diest PJ, Linn SC,et al: Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer.Br J Cancer 77: 621–626, 1998.
Powels TJ, Hickish TF, Makris TF,et al: Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer.J Clin Oncol 13: 547–552, 1995.
Kurerer HM, Newmann LA, Smith TL,et al: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.J Clin Oncol 17: 460–469, 1999.
Markis A, Powles TJ, Dowsett CK,et al: Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.Clin Cancer Res 3: 593–600, 1997.
Gusterson BA, Gelber RD, Goldhirsch A,et al: Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.J Clin Oncol 10: 1049–1056, 1992.
Chevallier B, Roche H, Olivier JP,et al: Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD). Results in high histological response rate.Am J Clin Oncol 16: 223–228, 1993.
Honkoop AH, van Diest PJ, de Jong JS,et al: Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer.Br J Cancer 77: 621–626, 1998.
Kurosumi M. Akiyama F, Tsuda H,et al: Histopathological criteria for assessment of therapeutic response in breast cancer.Breast Cancer 1: 1–2, 2001.
Francis ES, Shari LA, Larry JF,et al: Effects of preoperative chemotherapy on the morphology of respectable breast carcinoma.Mod Pathol 9: 893–900, 1996.
Ando M, Watanabe T, Nagata K,et al: Efficacy of docetaxel 60mg/m2 in patients with metastatic breast cancer according to the status of anthracycline resistance.J Clin Oncol 19: 336–342, 2001.
Clinical response to chemotherapy. In: World Health Organization ed, WHO handbook for reporting results of cancer treatment. Offset Publication, Geneva, pp 14–15, 1976.
Costa SD, Minckmiz G, Raab G,et al: The role of docetaxel (taxotere) in neoadjuvant chemotherapy of breast cancer.Semin Oncol 26: 24–31, 1999.
Machiavelli MR, Romero AO, Perez JE,et al: Prognostic significance of pathological response of primary tumor and metastatic lymph node after neoadjuvant chemotherapy for locally advanced breast carcinoma.The Cancer J from scie Am 4: 125–131, 1998.
Brifford M, Spyratos F, Tubiana-Hulin M,et al: Sequential cytopunctures during preoperative chemotherapy for primary breast carcinoma: Cytomorphorogic changes, initial tumor ploidity, and tumor regression.Cancer 63: 631, 1989.
Bonadonna G, Veronesi U, Brambillia C,et al: Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more.J Nalt Cancer Inst 82: 1539, 1990.
Morrow M, Braverman A, Thelmo W,et al: Multimodal therapy for locally advanced breast cancer.Arch Surg 121: 1291, 1986.
Frierson HF Jr, Fechner RE: Histologic grade of locally advanced infiltrating ductal carcinoma after treatment with induction chemotherapy.Am J Clinc Pathol 102: 154, 1994.
Kennedy S, Merino MJ, Swain SM,et al: The effects of hormonal and chemotherapy on tumoral and nonneoplastic breast tissue.Hum Pathol 21: 192, 1990.
Silverberg SG, Chitale AR: Assessment of significance of proportions of intraductal and infiltrating tumor growth in ductal carcinoma of the breast.Cancer 32: 830, 1973.
Hsu SM, Raine L, Franger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techinques: A comparison between ABC and unlabeled antibody (PAP) procedures.J Histochem Cytochem 29: 830, 1981.
Chevallier B, Roche H, Oliver JP,et al: Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD). Results in a high histologic responserate. Am J Clin Oncol 16: 223–228, 1997.
Monir HE, Mohamed MM, Hussein MK,et al: Pathological assessment of the response of locally advanced breast cancer to neoadjuvant chemotherapy and its implications for surgical management.Surg Today 30: 249–254, 2000.
Kuerer HM, Newman LA, Smith TL,et al: Clinical course of breast cancer patients with complete pathological primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.J Clin Oncol 17: 460–469, 1999.
Smith IC, Welch AE, Hutcheon AW,et al: Positron emission tomography using [18F]-fluorodeoxy-D-glucose to predict the pathologic response pf breast cancer to primary chemotherapy.J Clin Oncol 18: 1676–1688, 2000.
Author information
Authors and Affiliations
Corresponding author
Additional information
Reprint requests to Takashi Fukutomi, Department of Surgical Oncology, National Cancer Center Hospital, 1–-1 Tsukiji 5-chome, Chuo-ku, Tokyo 104-0045, Japan.
About this article
Cite this article
Matsuo, K., Fukutomi, T., Watanabe, T. et al. Concordance in pathological response to neoadjuvant chemotherapy between invasive and noninvasive components of primary breast carcinomas. Breast Cancer 9, 75–81 (2002). https://doi.org/10.1007/BF02967551
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02967551